Ambac Q2 total revenue up 8% to $55M; net loss widens to $72.7M as legacy sale nears approval

OCTAVE SPECIALTY GROUP INC

2025-Q2 EPS reported -$2.75 revenue$117,713,000

Total P&C premium production surged 110% to $346M, boosted by Beat acquisition.
Cirrata revenue up 148% to $33M; adjusted EBITDA to shareholders rose 28% to $3M.
Everspan combined ratio improved to 107% (down 270 bps) on lower loss ratio of 67.8%.
Net loss from continuing ops to Ambac shareholders $(20.5M) vs $(14.9M) a year ago; adjusted EPS $(0.22).
Wisconsin OCI recommends approval for AAC sale; hearing set Sept 3, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.